Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

6 treatments under study, led by Ino4212

Research Leaders

9 sponsors active, led by GeneOne Life Science, Inc.

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total

Phase 1 (1)

Phase 3 (1)

Trial Status

Completed1

Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials

NCT05959421Phase 3WithdrawnPrimary

Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure

NCT02464670Phase 1CompletedPrimary

Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

Showing all 2 trials

Research Network

Common Treatments

Ino42121
Ino4212 Ino90121
Ino42021
Ervebo Rvsvgzebovgp1
Ino42011

Active Sponsors

GeneOne Life Science, Inc.1
Bernhard Nocht Institute for Tropical Medicine1
Defense Advanced Research Projects Agency1
Goethe University1
Inovio Pharmaceuticals1

Ebola Vaccine